Breaking News Instant updates and real-time market news.

REGN

Regeneron

$307.43

(0.00%)

09:45
06/14/19
06/14
09:45
06/14/19
09:45

Regeneron data for REGN1979 'continues to impress,' says Piper Jaffray

Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals following updated Phase 1 results for REGN1979, a CD20xCD3 bispecific antibody, in B-cell non-Hodgkin lymphoma. The data "continues to impress," with 93% over response rate and 71% complete response in follicular lymphoma, Raymond tells investors in a research note. The analyst continue to see REGN1979 as an "up and coming value driver" and he keeps an Overweight rating on Regeneron with a $435 price target.

  • 14

    Jun

  • 26

    Jun

REGN Regeneron
$307.43

(0.00%)

05/20/19
LEHM
05/20/19
NO CHANGE
Target $315
LEHM
Underweight
Barclays still bearish on Regeneron despite 18% drop year-to-date
Barclays analyst Geoff Meacham says that despite the 18% decline of Regeneron Pharmaceuticals shares year-to-date, he remains bearish on the name with an Underweight rating and $315 price target. The analyst cites Eylea concentration risk and the near/long-term competitive threat in wet age-related macular degeneration. Pricing and/or share erosion in wet AMD from brolucizumab or DARPin could yield worse than consensus expectations, Meacham tells investors in a research note.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/21/19
PIPR
05/21/19
NO CHANGE
Target $435
PIPR
Overweight
Piper, confident in Street-high Dupixent estimates, says buy Regeneron
Piper Jaffray analyst Christopher Raymond says he's increasingly confident in his Street-high Dupixent estimates following his firm's latest dermatologist survey. The survey indicated "steepening use trends" for Regeneron Pharmaceuticals' Dupixent and a "meaningful inflection" in use for atopic dermatitis, Raymond tells investors in a research note. Further, the feedback suggests that the new adolescent atopic dermatitis label is already driving "meaningful growth as well as continued acceleration," adds the analyst. He recommends buying shares of Regeneron at current levels and keeps an Overweight rating on the name with a $435 price target.
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."

TODAY'S FREE FLY STORIES

HTH

Hilltop Holdings

$20.05

0.26 (1.31%)

08:03
06/27/19
06/27
08:03
06/27/19
08:03
Hot Stocks
Hilltop Holdings signs sponsored research agreement with GWU »

Hoth Therapeutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Aug

HQY

HealthEquity

$62.16

-2.5 (-3.87%)

08:03
06/27/19
06/27
08:03
06/27/19
08:03
Conference/Events
HealthEquity to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ALRN

Aileron Therapeutics

$0.75

-0.0365 (-4.63%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Hot Stocks
Aileron Therapeutics announces FDA acceptance of IND for ALRN-6924 »

Aileron Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$375.05

5.68 (1.54%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Boeing analyst commentary  »

BofA continues to see 6-9…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 24

    Jul

CABO

Cable One

$1,111.46

-18.95 (-1.68%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Cable One analyst commentary  »

Cable One price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$85.74

0.32 (0.37%)

08:01
06/27/19
06/27
08:01
06/27/19
08:01
Recommendations
VF Corp. analyst commentary  »

VF Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

TSLA

Tesla

$219.22

-0.47 (-0.21%)

08:00
06/27/19
06/27
08:00
06/27/19
08:00
Options
Tesla put buyer realizes 36% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:57
06/27/19
06/27
07:57
06/27/19
07:57
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

BB

BlackBerry

$7.55

-0.74 (-8.93%)

07:56
06/27/19
06/27
07:56
06/27/19
07:56
Recommendations
BlackBerry analyst commentary  »

BlackBerry execution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SM

SM Energy

$12.56

0.63 (5.28%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Initiation
SM Energy initiated  »

SM Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

07:55
06/27/19
06/27
07:55
06/27/19
07:55
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

ITRI

Itron

$60.88

0.48 (0.79%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Conference/Events
Itron to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

XEC

Cimarex Energy

$57.17

1.64 (2.95%)

07:53
06/27/19
06/27
07:53
06/27/19
07:53
Initiation
Cimarex Energy initiated  »

Cimarex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:52
06/27/19
06/27
07:52
06/27/19
07:52
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

LECO

Lincoln Electric

$79.77

0.1 (0.13%)

07:52
06/27/19
06/27
07:52
06/27/19
07:52
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$42.13

0.455 (1.09%)

07:50
06/27/19
06/27
07:50
06/27/19
07:50
Conference/Events
Eaton Vance to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$10.33

-0.13 (-1.24%)

07:50
06/27/19
06/27
07:50
06/27/19
07:50
Upgrade
Luther Burbank rating change at Sandler ONeill »

Luther Burbank upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.29

0.54 (2.73%)

07:49
06/27/19
06/27
07:49
06/27/19
07:49
Hot Stocks
Qiwi appoints Vladislav Poshmorga as CFO »

QIWI announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$23.58

-0.24 (-1.01%)

07:48
06/27/19
06/27
07:48
06/27/19
07:48
Upgrade
KB Home rating change  »

KB Home upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$42.28

-0.92 (-2.13%)

07:47
06/27/19
06/27
07:47
06/27/19
07:47
Recommendations
National Beverage analyst commentary  »

Guggenheim says National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIVE

Aerohive

$4.44

1.26 (39.62%)

07:46
06/27/19
06/27
07:46
06/27/19
07:46
Downgrade
Aerohive rating change at Craig-Hallum »

Aerohive downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$1.95

0.14 (7.73%)

07:45
06/27/19
06/27
07:45
06/27/19
07:45
Conference/Events
ImmunoGen to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ACRS

Aclaris Therapeutics

$4.45

0.06 (1.37%)

07:43
06/27/19
06/27
07:43
06/27/19
07:43
Downgrade
Aclaris Therapeutics rating change at SVB Leerink »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$23.45

-0.38 (-1.59%)

07:43
06/27/19
06/27
07:43
06/27/19
07:43
Hot Stocks
Apellis complete enrollment of Phase 3 APL-2 head-to-head study »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

TRIP

TripAdvisor

$44.04

-0.47 (-1.06%)

07:41
06/27/19
06/27
07:41
06/27/19
07:41
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.